FIELD: biotechnology.
SUBSTANCE: invention relates to a pharmaceutical composition containing: engineered regulatory T-cell having elimination or reduction of steroid receptor coactivator-3 (SRC-3) expression compared to the level of gene product expression in the absence of such elimination or reduction in the cell; and one or more agents targeting SRC-3. Also disclosed is a method of producing regulatory T-cells having elimination or reduction of steroid receptor coactivator-3 (SRC-3) expression, including a step of eliminating or reducing the expression of SRC-3 in regulatory T-cells compared to the level of expression of the gene product in the absence of such elimination or reduction in the cell.
EFFECT: invention is effective for treating cancer in an individual.
48 cl, 7 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | 2016 |
|
RU2761980C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| MATERIALS AND METHODS FOR CANCER TREATMENT | 2019 |
|
RU2787828C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
| COMPOSITIONS AND METHODS FOR INHIBITING T-CELL DEPUTY | 2018 |
|
RU2804282C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| MODIFIED IMMUNOREGULATORY ELEMENT AND IMMUNITY CHANGE BY THIS ELEMENT | 2017 |
|
RU2767206C2 |
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
